

U.S. NUCLEAR REGULATORY COMMISSION

Date: Jan. 9 & 10, 2007

TELEPHONE CONVERSATION RECORD

Time: Various

Mail Control 139714 License No(s). 19-30688-01 Docket No(s). 03035856
or Report No(s).

Name of Licensee: Locus Pharmaceuticals, Inc.

Name of Participant(s): Eric Springman
Farrah Gaskins

Telephone No. 215-358-2009

Subject: Amendment to remove I-125

(NOTE: This will be used as the Documents Title in ADAMS)

Summary:

1/9, 8:50am: In the amendment, the licensee requests that I-125 be removed from their license. One authorized user, Katrina Northrop, is only authorized for the use of I-125. I contacted Dr. Springman to inquire if this AU would be removed. Left message.

Dr. Springman returned the call and left a message for me on voice mail. He inquired if the NRC would approve the license having a condition stating that authorized users would be properly trained for licensed material usage rather than naming users. He said there is a lot of turnover within the company and this statement would help decrease the paperwork.

1/10, 10:11am. I spoke to Dr. Springer and informed him that we could not approve such a statement for the type of license that Locus has. I informed him that there would need to be at least one authorized user named on the license and explained to him the responsibility the authorized user has if others were to work under the supervision of him/her. He said that he understood and that he actually would like to take a few of the au's from the license as well. I told him that he could send in a letter referencing the MC # and I could complete the request as part of the same amendment.

Action Required: Waiting on fax from licensee

Document Availability: Publicly Available Non-Publicly Available

Non-Sensitive Non-Sensitive Copyright Sensitive Sensitive Copyright

Immediate Release Normal Release Delay Release Date

Prepared & SUNSI Review Completed By: Farrah Gaskins / RA / Date: 01/11/07